Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Day One Biopharmaceuticals Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bioxcel Therapeutics (BTAI – Research Report) and Day One Biophar...

Current Quarter	$-0.18	Next Quarter	$-0.36
Current Year	$-0.98	Next Year	$-0.72
QoQ Growth	-100.0%	YoY Growth	+26.5%
3Y EPS CAGR	+39.6%	Target Price	$23.00
Consensus	Buy	Upside	+175.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DAWN	$8.36	-0.71%	1.21M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DAWN	$8.36	-0.7%	1.21M
3
4
5
6

DAWN

DAWN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Day One Biopharmaceuticals Inc. Data in Excel

Get Day One Biopharmaceuticals Inc. Data in Excel